Eisai Slashes Lecanemab Sales Forecasts
July 23, 2026
Welcome to the new format of Greg’s Alzheimer’s Research Report.
Each report now begins with a brief summary, allowing you to instantly assess its relevance, grasp the core insights, and decide if the full piece warrants a deeper dive.
On average, I spend three hours producing each report. This rigorous process involves scouring scientific journals for critical topics, tracking clinical trial updates, and analyzing extensive background data to bring you accurate, actionable information.
Effective July 14, 2026, our format will change. The brief report summaries will remain free to all readers, while access to the complete, in-depth reports will transition to a paid subscription model.
This subscription directly supports the time and research required to sustain this platform. We offer three ways to stay informed:
Monthly Subscription: $10 per month
Annual Subscription: $100 per year (Save $20 annually)
Founder’s Circle: $250 per year (Includes an exclusive monthly video conference to discuss emerging Alzheimer’s treatments in close detail)
SUMMARY
Lecanemab is a controversial Alzheimer’s (AD) drug designed to slow the progression of the disease. Many experts question if Lecanemab’s high cost, safety concerns, and modest benefit are worth AD patients taking the infused drug.
In this report, I present Lecanemab financial data obtained from investor reports. Eisai (the codeveloper along with Biogen) of Lecanemab is bullish on the future of their AD therapies. Please subscribe to read this report and support my Alzheimer’s treatment..
